{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:13:26Z","timestamp":1791180806280,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.4158\/ep.13.6.656","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T21:48:28Z","timestamp":1365198508000},"page":"656-661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and Safety of Pioglitazone in Treatment of a Patient with an Atypical Partial Lipodystrophy Syndrome"],"prefix":"10.1016","volume":"13","author":[{"given":"Gina G.","family":"Sleilati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Leff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Bonnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP.13.6.656_bb0005","doi-asserted-by":"crossref","first-page":"22252229","DOI":"10.1161\/01.CIR.103.18.2225","article-title":"Premature atherosclerosis associated with monogenic insulin resistance","volume":"103","author":"Hegele","year":"2001","journal-title":"Circulation"},{"key":"10.4158\/EP.13.6.656_bb0010","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1043-2760(03)00142-5","article-title":"Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome","volume":"14","author":"Hegele","year":"2003","journal-title":"Trends Endocrinol Metab"},{"issue":"Pt 5","key":"10.4158\/EP.13.6.656_bb0015","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1042\/BST0331073","article-title":"Diseases of adipose tissue: genetic and acquired lipodystrophies","volume":"33","author":"Capeau","year":"2005","journal-title":"Biochem Soc Trans"},{"key":"10.4158\/EP.13.6.656_bb0020","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/ncpcardio0638","article-title":"Genetic determinants of the metabolic syndrome","volume":"3","author":"Pollex","year":"2006","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.4158\/EP.13.6.656_bb0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","article-title":"Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature","volume":"83","author":"Misra","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.4158\/EP.13.6.656_bb0030","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/505885","article-title":"Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy","volume":"79","author":"Hegele","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.4158\/EP.13.6.656_bb0035","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2337\/diacare.26.6.1819","article-title":"K\u00f6bberling type of familial partial lipodystrophy: an underrecognized syndrome","volume":"26","author":"Herbst","year":"2003","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.6.656_bb0040","first-page":"99","article-title":"Review: peroxisome proliferator-activated receptor-gamma and its role in the development and treatment of diabetes","volume":"5","author":"Leff","year":"2004","journal-title":"Exp Diabesity Res"},{"issue":"Suppl 1","key":"10.4158\/EP.13.6.656_bb0045","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/sj.ijo.0802911","article-title":"Lessons from human mutations in PPARgamma","volume":"29","author":"Hegele","year":"2005","journal-title":"Int J Obes (Lond)"},{"key":"10.4158\/EP.13.6.656_bb0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cmet.2006.09.003","article-title":"Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance","volume":"4","author":"Agostini","year":"2006","journal-title":"Cell Metab"},{"key":"10.4158\/EP.13.6.656_bb0055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-133-4-200008150-00009","article-title":"Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes","volume":"133","author":"Arioglu","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP.13.6.656_bb0060","doi-asserted-by":"crossref","first-page":"9856","DOI":"10.1073\/pnas.92.21.9856","article-title":"Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C\/EBP alpha","volume":"92","author":"Hu","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.4158\/EP.13.6.656_bb0065","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.2337\/diab.46.7.1230","article-title":"PPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subjects","volume":"46","author":"Park","year":"1997","journal-title":"Diabetes"},{"key":"10.4158\/EP.13.6.656_bb0070","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1172\/JCI118703","article-title":"Regulation of PPAR gamma gene expression by nutrition and obesity in rodents","volume":"97","author":"Vidal-Puig","year":"1996","journal-title":"J Clin Invest"},{"key":"10.4158\/EP.13.6.656_bb0075","doi-asserted-by":"crossref","first-page":"31771","DOI":"10.1074\/jbc.271.50.31771","article-title":"Insulinand mitogenactivated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma","volume":"271","author":"Zhang","year":"1996","journal-title":"J Biol Chem"},{"key":"10.4158\/EP.13.6.656_bb0080","doi-asserted-by":"crossref","first-page":"20230","DOI":"10.1074\/jbc.272.32.20230","article-title":"Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma): differential activity of PPARgamma1 and -2 isoforms and influence of insulin","volume":"272","author":"Werman","year":"1997","journal-title":"J Biol Chem"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20428162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20428162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/6G4067784R3X312M.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:47:59Z","timestamp":1761515279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20428162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S1530891X20428162"],"URL":"https:\/\/doi.org\/10.4158\/ep.13.6.656","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Pioglitazone in Treatment of a Patient with an Atypical Partial Lipodystrophy Syndrome","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP.13.6.656","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}